SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Casdin Capital, LLC

CIK 0001534261 · 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK, NY, 10019 · 212-554-4952

Reported Value
$1.1B
Q2 2023
Positions
41
Filings on Record
33
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Casdin Capital, LLC reported $1.1B in U.S.-listed holdings across 41 positions for Q2 2023.

Its largest position, BLFS, represents 14.9% of the portfolio.

Compared with Q1 2023, the fund opened 6 new positions and exited 5.

Portfolio Metrics

Turnover
+14.2%
vs prior filed quarter
Top-10 Concentration
+63.1%
share of reported value
Largest Position
+14.9%
Biolife Solutions
New / Exited
6 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $585MQ4 ’18Q1 ’19: $910MQ3 ’19: $1.74TQ1 ’20: $942MQ2 ’20: $1.7BQ2 ’20Q3 ’20: $2.2BQ4 ’20: $3.4BQ1 ’21: $3.4BQ2 ’21: $3.9BQ2 ’21Q3 ’21: $4.0BQ4 ’21: $3.5BQ1 ’22: $2.2BQ2 ’22: $1.2BQ2 ’22Q3 ’22: $1.5BQ4 ’22: $1.3BQ1 ’23: $1.2BQ2 ’23: $1.1BQ2 ’23Q3 ’23: $904MQ4 ’23: $1.0BQ1 ’24: $1.3BQ2 ’24: $1.3BQ2 ’24Q3 ’24: $1.5BQ4 ’24: $1.5BQ1 ’25: $1.2BQ2 ’25: $1.1BQ2 ’25Q3 ’25: $1.2BQ4 ’25: $1.6BQ1 ’26: $1.3Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 85.8%Other: 10.4%ADR: 3.8%
  • Common Stock · 85.8% · $982M
  • Other · 10.4% · $119M
  • ADR · 3.8% · $43M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CTLTEURCATALENT INCNEW+720.0K720.0K+$31M$31M
WGSGENEDX HOLDINGS CORPNEW+3.10M3.10M+$18M$18M
SANASANA BIOTECHNOLOGY INCNEW+750.0K750.0K+$4M$4M
SG7SAGE THERAPEUTICS INCNEW+90.0K90.0K+$4M$4M
FLBSTANDARD BIOTOOLS INCNEW+1.20M1.20M+$2M$2M
SCILEX HOLDING CONEW+23.5K23.5K+$130,962$130,962
SMFRUSDGENEDX HOLDINGS CORPSOLD OUT−102.15M0−$37M$0
PROMETHEUS BIOSCIENCES INCSOLD OUT−150.0K0−$16M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

41 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BLFSBIOLIFE SOLUTIONS INChistory →COM NEW14.91%$171M7.72M
2SRPTSAREPTA THERAPEUTICS INChistory →COM10.16%$116M1.01M
3RLAYRELAY THERAPEUTICS INChistory →COM6.58%$75M6.00M
4EQRX INCCOM6.43%$74M39.53M
5ALNYALNYLAM PHARMACEUTICALS INChistory →COM4.65%$53M280.0K
6NTLAINTELLIA THERAPEUTICS INChistory →COM4.54%$52M1.27M
7RVMDREVOLUTION MEDICINES INChistory →COM4.23%$48M1.81M
8EXKEXACT SCIENCES CORPhistory →COM4.10%$47M500.0K
9VERVE THERAPEUTICS INCCOM3.87%$44M2.36M
10GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS3.62%$41M997.0K
112655787DBLUEPRINT MEDICINES CORPhistory →COM3.42%$39M620.0K
12DNLIDENALI THERAPEUTICS INChistory →COM3.35%$38M1.30M
13TNYATENAYA THERAPEUTICS INChistory →COM3.27%$37M6.38M
14CTLTEURCATALENT INChistory →COM2.73%$31M720.0K
15PLRXPLIANT THERAPEUTICS INChistory →COM2.69%$31M1.70M
16SOMALOGIC INCCLASS A COM2.54%$29M12.60M
17ILMNILLUMINA INChistory →COM2.54%$29M155.0K
18MXCTGBXMAXCYTE INChistory →COM1.89%$22M4.71M
19TSVT*2SEVENTY BIO INChistory →COMMON STOCK1.79%$20M2.02M
20FDMT4D MOLECULAR THERAPEUTICS INhistory →COM1.69%$19M1.07M
21WGSGENEDX HOLDINGS CORPhistory →COM CL A1.61%$18M3.10M
22BEAMBEAM THERAPEUTICS INChistory →COM1.59%$18M570.0K
23ABCLABCELLERA BIOLOGICS INChistory →COM1.42%$16M2.52M
24IPSCCENTURY THERAPEUTICS INChistory →COM0.89%$10M3.21M
25FATEFATE THERAPEUTICS INCCOM0.85%$10M2.05M
26RNAGBPAVIDITY BIOSCIENCES INCCOM0.82%$9M850.0K
27TWSTTWIST BIOSCIENCE CORPCOM0.80%$9M450.0K
28PRMEPRIME MEDICINE INCCOM0.47%$5M367.2K
29INCYINCYTE CORPCOM0.42%$5M77.5K
30SANASANA BIOTECHNOLOGY INCCOM0.39%$4M750.0K
31SG7SAGE THERAPEUTICS INCCOM0.37%$4M90.0K
32GLUEMONTE ROSA THERAPEUTICS INCCOM0.31%$3M510.9K
33TNGXTANGO THERAPEUTICS INCCOM0.29%$3M1.00M
34FLBSTANDARD BIOTOOLS INCCOM0.20%$2M1.20M
35ABSIABSCI CORPORATIONCOM0.18%$2M1.37M
36EXAIEUREXSCIENTIA PLCADS0.11%$1M213.9K
37SINGULAR GENOMICS SYSTEMS INCOM0.10%$1M1.35M
38MRTXEURMIRATI THERAPEUTICS INCCOM0.08%$860,40023.8K
39LIANYLIANBIOSPONSORED ADS0.04%$470,626206.4K
40KRON1USDKRONOS BIO INCCOM0.02%$213,003123.8K
41SCILEX HOLDING COCOM0.01%$130,96223.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$1.3B40May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$1.6B38Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$1.2B32Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$1.1B33Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.2B44May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.5B35Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.3B38Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$1.3B37May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.0B38Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$904M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.1B41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$1.2B41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.3B46Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.5B37Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.2B40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$2.2B47May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$3.5B53Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.0B54Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.9B54Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$3.4B48May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.4B52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.2B45Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B42Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$942M38May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019Under review32Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019REVEALED$1.74T59Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019Under review31Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$910M29May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$585M31Feb 13, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.